Dirk Van Gestel

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 12

Top Venues

Cancers

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Institut Jules Bordet

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Institut Jules Bordet Mar 01 2015

Belgium

Head of department :: Radiation Oncology

Publications

Sofian Benkhaled, Cedric Peters, Nicolas Jullian, Tatjana Arsenijevic, Julie Navez, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem, Christelle Bouchart
Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy? Cancers 15 (3) (2023)
Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E Ghanem, Dirk Van Gestel
Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11 , 1093. Cancers 15 (24) (2023)
Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E Ghanem, Dirk Van Gestel
Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11 , 1093. Cancers 15 (24) (2023)
Sofian Benkhaled, Cedric Peters, Nicolas Jullian, Tatjana Arsenijevic, Julie Navez, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem, Christelle Bouchart
Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy? Cancers 15 (3) (2023)
Martin Manderlier, Julie Navez, Matthieu Hein, Jean-Luc Engelholm, Jean Closset, Maria Antonietta Bali, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem, Christelle Bouchart
Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation. Cancers 14 (23) (2022)
Martin Manderlier, Julie Navez, Matthieu Hein, Jean-Luc Engelholm, Jean Closset, Maria Antonietta Bali, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem, Christelle Bouchart
Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation. Cancers 14 (23) (2022)
Hamza Alghamdi, Jennifer Dhont, Mohammad Krayem, Pauline De Bruyn, Benedikt Engels, Dirk Van Gestel, Robbe Van den Begin
The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease. Cancers 14 (8) (2022)
Martin Manderlier, Julie Navez, Matthieu Hein, Jean-Luc Engelholm, Jean Closset, Maria Antonietta Bali, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem, Christelle Bouchart
Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation. Cancers 14 (23) (2022)
Martin Manderlier, Julie Navez, Matthieu Hein, Jean-Luc Engelholm, Jean Closset, Maria Antonietta Bali, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem, Christelle Bouchart
Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation. Cancers 14 (23) (2022)
Carlos Artigas, Romain Diamand, Qaid Ahmed Shagera, Nicolas Plouznikoff, Fabrice Fokoue, François-Xavier Otte, Thierry Gil, Alexandre Peltier, Dirk Van Gestel, Patrick Flamen
Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact. Cancers 13 (19) (2021)
Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E Ghanem, Dirk Van Gestel
The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 11 (8) (2019)
Julie Schatteman, Dirk Van Gestel, Dieter Berwouts, Werner De Gersem, Geert De Kerf, Wilfried De Neve, Bie De Ost, Ana Maria Luiza Olteanu, Sylvie Rottey, Tom Vercauteren, Ingeborg Goethals, Fréderic Duprez
A feasibility study on adaptive 18F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territory. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 194 (8) (2018)

Dirk Van Gestel.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Dirk Van Gestel